Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 6, Issue 9, Pages 1163-1167Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.6.9.1163
Keywords
androgen-independent prostate cancer; antigen-presenting cells; dendritic cells; Gleason score; hormone refractory prostate cancer; sipuleucel-T
Categories
Ask authors/readers for more resources
Sipuleucel-T (Provenge(R); APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes autologous dendritic cells pulsed ex vivo with a recombinant fusion protein (PA2024) consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase. Two Phase 11 trials in men with androgen-dependent biochemically relapsed prostate cancer have demonstrated a decrease in prostate-specific antigen and prolongation in prostate-specific antigen doubling time. In men with hormone-refractory prostate cancer, clinical trials have demonstrated both biological activity and clinical response to sipuleucel-T. Data from two Phase III trials in men with asymptomatic, metastatic hormone-refractory prostate cancer demonstrated an improved median overall survival in men who received sipuleucel-T compared with placebo. Clinical trials are ongoing or are being developed to evaluate sipuleucel-T in various prostate cancer disease states and in combination with other treatment modalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available